CR Pharma In-licenses Rights To Prostate Cancer Drug from Xbrane

China Resource Pharmaceutical Group acquired China rights to a long-acting treatment for prostate cancer developed by Sweden 's Xbrane Biopharma. Spherotide is triptorelin, a GnRH analogue, in a parenteral depot formulation. CR Pharma will pay an initial license fee (described as a high single-digit million dollar amount) and unspecified milestones through China market authorization. Xbrane will supply the product while CR Pharma will be responsible for China clinical trials and other regulatory matters. More details.... Stock Symbol: (HK: 3320) Share this with colleagues: // //